Molecular Formula | C33H35FN2O5 |
Molar Mass | 558.65 |
Density | 1.23±0.1 g/cm3(Predicted) |
Melting Point | 176-178°C |
Boling Point | 722.2±60.0 °C(Predicted) |
pKa | pKa 4.46(H2O t=30 Iuncontrolled) (Uncertain) |
Storage Condition | 2-8°C |
Physical and Chemical Properties | Melting point 176-178°C |
Use | Used as hypolipidemic drug |
Hazard Symbols | Xn - Harmful |
Risk Codes | R20/21/22 - Harmful by inhalation, in contact with skin and if swallowed. R36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. |
HS Code | 35040000 |
2-(4 fluorophenyl)-p carbonyl 8 hydroxy -5-(1-methyl ethyl)-3-phenyl 4 [(phenyl amino) carbonyl]-1H-pyrrole-1-heptanoic acid tert-butyl alcohol is reduced with triethylboron and sodium borohydride in methanol, and the product is hydrolyzed to obtain sodium atovastatin. Atovastatin is available via acidification. Atopastatin was refluxed in toluene to give atopastatin lactone.
Pfizer co-launched with the company Parke-Davis and was launched in 19, 9, 7. Hypolipidemic drug. Can significantly reduce low density lipoprotein cholesterol and triglyceride levels. Can inhibit the activity of HMG-CoA reductase, thus reducing cholesterol synthesis.